A licence is expected to be granted for MabThera - an established treatment for non-Hodgkins lymphoma (NHL) - as a rheumatoid arthritis medication in the second quarter of next year.
The campaign will involve advocacy development, medical education and presentation of data on a two-year trial of the drug at the American College of Rheumatology 12-17 November conference in San Diego for the UK market.
Red Door won the business after a four-way pitch. Red Door associate director Catherine Devaney reports to Roche UK head of product comms Susie Hackett on the business.
Roche continues to use Ketchum to handle its UK PR for MabThera's NHL indication.